Table 1.

Demographics of patients and characteristics of treatments administered

NMA (n = 33)6 Gy TBI (n = 23)
Sex
 Male1413
 Female1910
Age (years)
 ≤300 30 3
 30–390 60 5
 40–49120 4
 50–591011
 ≥600 20 0
HLA-A2±
 Yes1110
 No2213
Prior IL-2
 Yes2511
 No0 812
Stage of disease
 M1a0 20 1
 M1b1110
 M1c2012
Cell number (×109)a47.7 (±3.3)43.1 ( ± 7.5)
IL-2 (doses)6.3 (±0.3)7.5 (±0.5)
Age of cells at Infusion (days)32.7 (±0.7)35.4 (±1.3)
CD4+ cells (%)
 Prior to CD8+ enrichment21.8 (±3.2)22.7 (±3.6)
 Infused0.6 (±0.3)2.1 (±0.8)
CD8+ cells (%)
 Prior to CD8+ enrichment57.2 (±4.3)49.0 (±4.7)
 Infused96.0 (±0.6)97.3 (±0.8)
Tissue of TIL originb
 Lymph node160 6
 Subcutaneous100 7
 Liver0 40 3
 Lung0 30 5
 Large bowel0 00 1
 Intramuscular0 00 2
 Other visceral site0 20 1
  • aAverage (± SE).

  • bSome patients were treated with TIL from multiple tissues of origin.